Advanced Instruments, a leading global provider of osmolality testing instrumentation and consumables for the biopharmaceutical, clinical and food & beverage industries, has signed an agreement to acquire Solentim, a global leader in innovative solutions for cell line development of biopharmaceutical products.
The acquisition of Solentim adds a highly complementary, differentiated and innovative portfolio of bioprocessing instruments and consumables to Advanced Instruments, and significantly expands the commercial and R&D capabilities of Advanced Instruments' biopharmaceuticals business.
For the twelve-month period ending
The total consideration amounts to approximately
"We are very pleased with the performance of Advanced Instruments so far during our ownership. A key priority for us is to grow our great platform companies within
"We are excited to complete our first strategic add-on acquisition for Advanced Instruments. The combination of Advanced Instruments and Solentim creates a leading bioprocessing instrument and consumables franchise. We see strong complementarity between the two businesses, and significant opportunities to use the strength of their combined commercial and R&D capabilities to drive global growth and create long-term value. We look forward to working with Advanced Instruments to further develop the business", says
Closing is expected during the third quarter of 2021.
About
About Advanced Instruments
Advanced Instruments is the leading global provider of osmolality testing instrumentation and consumables for the clinical, biopharmaceutical, and food & beverage markets. With a strong brand reputation and deep customer relationships, it is recognized as the global authority on osmolality testing, and its products are the standard within each of its core markets. Advanced Instruments is based in
About Solentim
Solentim is the trusted global leader in workflows for antibody and cell-based therapies. Solentim's assurance rich technologies enable the isolation, growth and characterization of high value cells while its data-driven platform enables smarter decision making earlier in the cell line development process. Solentim's products enable biopharmaceutical companies to experience faster workflows, confidently designed for regulatory environments.
For further information:
Phone +46 70 550 3500
viveka.hirdman-ryrberg@investorab.com
Magnus Dalhammar, Head of Investor Relations,
Phone +46 73 524 2130
magnus.dalhammar@investorab.com
Our press releases can be accessed at www.investorab.com
Investor, founded by the Wallenberg family in 1916, is an engaged owner of high quality global companies. We have a long-term investment perspective. Through board participation, as well as industrial experience, our network and financial strength, we work continuously to support our companies to remain or become best-in-class. Our holdings include, among others, ABB,
https://news.cision.com/investor/r/patricia-industries-to-fund-strategic-add-on-acquisition-by-advanced-instruments,c3392505
https://mb.cision.com/Main/1084/3392505/1450927.pdf
(c) 2021 Cision. All rights reserved., source